WHITE PAPER

The timely release of safe and efficacious cell and gene therapeutics depends on many factors. One is the availability of analytical platforms that can quickly deliver reliable data on viral titer and process-related impurities. There are many factors to consider when choosing a platform to ensure high productivity.

This white paper provides an overview of the viral vector landscape and its use in cell and gene therapy, with a focus on lentiviral vectors and adeno-associated viral (AAV) vectors. The requirements for immunoassays in viral vector bioprocess analytics are discussed in detail and Gyrolab^® case studies from viral vector analytical labs are presented. Find out how many labs are experiencing improved productivity when implementing the Gyrolab technology in their bioprocess analytical workflows